What is Autolus Therapeutics plc's (AUTL) StockRank?

MoatMap's StockRank for Autolus Therapeutics plc (AUTL) is 23/100, with a Sell signal. This is a composite score combining Quality (24), Value (40), and Momentum (49) factor ranks across MoatMap's 20,000+ stock universe.

Does Autolus Therapeutics plc have an economic moat?

Autolus Therapeutics plc (AUTL) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Autolus Therapeutics plc a buy, hold, or sell?

MoatMap's current signal for Autolus Therapeutics plc (AUTL) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Autolus Therapeutics plc in?

Autolus Therapeutics plc (AUTL) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AUTL

SELLREMOVE

Autolus Therapeutics plc · Healthcare · United Kingdom · $471M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-29.6%

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Autolus is a clinical-stage biopharmaceutical company with negative cash flows and high cash burn. It does not fit our quality compounder model and lacks the predictable owner earnings required by the Buffett lens.

COMPANY DESCRIPTION

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development of programmed T-cell therapies for the treatment of cancer. The company advances a proprietary pipeline of next-generation CAR T-cell therapies, designed to overcome limitations of current treatments through sophisticated cell engineering. It is a specialized biotechnology firm at the forefront of cellular immunotherapy, aiming to deliver innovative and highly effective treatments for hematological and solid tumors.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	CAGR
Revenue	2M	6M	2M	10M	88.7%
EPS	-1.97	-1.57	-1.20	-0.86	—
Shares	91M	173M	174M	266M	+192.7%
Debt	21M	24M	53M	53M	35.8%
Equity	313M	299M	111M	427M	10.9%
Op CF	-118M	-112M	-146M	-206M	—
Inv CF	-9M	-11M	-11M	-395M	—
Fin CF	284M	224M	-883,000	590M	—

PRICE (1M)-10.0%

SMA 50SMA 200

$1.53

RSI (14)

35.0

52W High

$2.70

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-48.3%14.8

ROE

-29.6%25.5

GP/Assets

-4.5%7.7

Op. Margin

-6570.7%2.7

FCF/Assets

—N/A

Piotroski

—7.2

Int. Cover

-6.8x28.2

D/E Ratio

—N/A

Current Ratio

11.05x88.6

Value

P/E (TTM)

—N/A

EV/EBITDA

2.3x60.9

P/FCF

—N/A

P/B

0.3x92.6

P/S

385.0x4.1

Div Yield

—N/A

Momentum

52W High %

57%33.9

RS 6M

-15%63.2

SMA 50/200

1.03x69.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+42%50.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$471M

P/E (Forward)

-2.5x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AUTL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AUTL	Autolus Therapeutics plc(you)	$471M	23	SELL
AVCT.L	Avacta Group Plc	$472M	13	STRONG SELL
BCYC	Bicycle Therapeutics plc	$326M	11	STRONG SELL
SCLP.L	Scancell Holdings plc	$333M	36	HOLD
OXB.L	Oxford Biomedica plc	$1.0B	36	HOLD
ONT.L	Oxford Nanopore Technologies plc	$1.9B	30	SELL
TLSA	Tiziana Life Sciences Ltd	$186M	1	STRONG SELL
IMCR	Immunocore Holdings plc	$1.5B	44	HOLD
4BB.L	4basebio PLC	$110M	4	STRONG SELL
HEMO.L	Hemogenyx Pharmaceuticals Plc	$63M	14	STRONG SELL

Peer medians: ROE 1.2% · P/E 26.9x · Gross margin 51.4%

Autolus Therapeutics plc (AUTL) — Stock Score Summary

Autolus Therapeutics plc (AUTL) has a MoatMap StockRank of 23/100 based on Quality (24/100), Value (40/100), and Momentum (49/100) factor scores. The current signal is SELL. Autolus is a clinical-stage biopharmaceutical company with negative cash flows and high cash burn. It does not fit our quality compounder model and lacks the predictable owner earnings required by the Buffett lens.

Key Financial Metrics

Price	$1.53
Market Cap	$471M
P/E (Forward)	-2.48
Price/Book	0.26
Return on Equity	-29.6%
Return on Invested Capital	-48.3%
Gross Margin	0.0%
Operating Margin	-6570.7%

Autolus Therapeutics plc operates in the Biotechnology industry, part of the Healthcare sector (United Kingdom).

Frequently Asked Questions

What is Autolus Therapeutics plc’s (AUTL) StockRank?: MoatMap’s StockRank for Autolus Therapeutics plc (AUTL) is 23/100, with a Sell signal. It is a composite of Quality (24), Value (40), and Momentum (49) factor ranks across MoatMap’s 20,000+ stock universe.
Does Autolus Therapeutics plc have an economic moat?: Autolus Therapeutics plc (AUTL) has a Quality factor score of 24/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Autolus Therapeutics plc a buy, hold, or sell?: MoatMap’s current signal for Autolus Therapeutics plc (AUTL) is Sell, based on a StockRank of 23/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Autolus Therapeutics plc in?: Autolus Therapeutics plc (AUTL) operates in the Healthcare sector, specifically the Biotechnology industry (United Kingdom).